Aarti Drugs Limited (NSE:AARTIDRUGS)
477.35
+2.30 (0.48%)
Jul 9, 2025, 3:29 PM IST
Aarti Drugs Revenue
In the fiscal year ending March 31, 2025, Aarti Drugs had annual revenue of 23.87B INR, down -5.60%. Aarti Drugs had revenue of 6.77B in the quarter ending March 31, 2025, with 9.16% growth.
Revenue
23.87B
Revenue Growth
-5.60%
P/S Ratio
1.83
Revenue / Employee
22.43M
Employees
1,064
Market Cap
43.68B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 23.87B | -1.42B | -5.60% |
Mar 31, 2024 | 25.29B | -1.87B | -6.90% |
Mar 31, 2023 | 27.16B | 2.27B | 9.14% |
Mar 31, 2022 | 24.89B | 3.34B | 15.49% |
Mar 31, 2021 | 21.55B | 3.49B | 19.31% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 525.78B |
Divi's Laboratories | 93.60B |
Cipla | 272.67B |
Apollo Hospitals Enterprise | 217.94B |
Mankind Pharma | 122.07B |
Zydus Lifesciences | 232.42B |
Aurobindo Pharma | 317.24B |
Fortis Healthcare | 77.83B |
Aarti Drugs News
- 2 months ago - Aarti Drugs share price jumps 6% as Q4 EBITDA rises 8.9% YoY to Rs 93.4 crore - Business Upturn
- 2 months ago - Aarti Drugs Q4 results: Revenue up 9.1% YoY to Rs 676.76 crore, Net profit rises 32% YoY - Business Upturn
- 5 months ago - Aarti Drugs receives US FDA clearance, removed from Import Alert 66-40 - Business Upturn
- 5 months ago - Aarti Drugs Ltd (BOM:524348) Q3 2025 Earnings Call Highlights: Navigating Revenue Decline with ... - GuruFocus
- 5 months ago - Aarti Drugs shares surge despite Q3 FY25 EBITDA margin falls to 11.1% - Business Upturn
- 5 months ago - Aarti Drugs Q3 FY25 results: Revenue down 8% to Rs 556.6 crore, Net Profit flat at Rs 37.09 crore - Business Upturn
- 7 months ago - Aarti Drugs shares surge 15% after receiving EIR from USFDA for API plant in Tarapur - Business Upturn
- 9 months ago - Aarti Drugs shares fall over 2% following poor Q2 FY25 results - Business Upturn